Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

Overview of attention for article published in Frontiers in immunology, June 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 6 X users

Readers on

mendeley: 13 Mendeley

Summary X

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 56,380 followers.

RT @manuelmuro5: La mayoría de los pacientes con Esclerosis Múltiple, Miastenia gravis y Neuromielitis óptica desarrollaron una respuesta d…

19 Jun 2023

Reply Repost Favourite

La mayoría de los pacientes con Esclerosis Múltiple, Miastenia gravis y Neuromielitis óptica desarrollaron una respuesta de células T específica del SARS-CoV2. La vacunación puede inducir anticuerpos en una parte de los pacientes tratados con anti-CD20....

19 Jun 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or oc…

18 Jun 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or oc…

18 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.